Build Your Longevity-Biotech Evaluation Skills
For investors and financial professionals without a biology background. Learn a repeatable way to examine scientific evidence, valuation, cash runway, dilution and the next milestone using EverLife's 25-Gate Framework.
Study the process through plain-English explanations, practical exercises and worked company cases. View the curriculum and current enrollment terms before joining.
Before investing $10,000+ in a longevity biotech, build the skill to evaluate it yourself.
This is what I wish I’d had before losing $10,000 in each of my first two longevity biotech investments. Both sounded promising.
Build your experience alongside me, evaluating private, microcap and other public companies with the 25-Gate Framework, developed specifically for longevity biotech.
Build your own judgment, one skill each week. Practice one of the 25 gates on a real company, then compare your assessment with mine.
You don’t need every headline.
You need to understand what matters.
I spend the hours studying the science, evaluating companies, and listening to investment pitches and investor discussions. You get the most useful lessons in two short, focused emails each week.
Understand how treatments work. Practice evaluating the companies behind them. Build the skill to assess the next pitch yourself.
Less noise. More understanding. Skills you can use.
RESEARCH RECORD · THROUGH SEPTEMBER 24, 2026
21 companies followed. One clinical setback documented since admission.
We evaluate companies with the 25-Gate Framework, preserve the dated assessment, then follow the evidence.
| Research list | Documented clinical setbacks |
|---|---|
| Tracker | 0 of 11 · 0% |
| Scout | 1 of 10 · 10% |
| Overall | 1 of 21 · 4.8% |
Five companies have documented clinical or regulatory progress. For the other 15, no qualifying milestone or clinical setback has been verified in this record.
The setback was Longeveron’s missed primary trial endpoint. The five progress cases are Repair, Cyclarity, ProKidney and BioAge in Tracker, and Serina in Scout.
Not a success rate or investment return. These counts describe the events verified in this record, not a complete audit of every company development. No documented setback does not mean success or low risk. Follow-up periods differ, and outcomes are still developing.
View the dated assessments, sources and updates →
Build the skill to evaluate longevity biotechs yourself.
Practice one framework skill each week, then compare your assessment with mine.
90-Day Money-Back Guarantee
Give it 90 days. If you don’t feel the skills you’re building are worth at least 10 times your membership fee, let me know for a full refund. No questions asked.
Email [email protected] within 90 days of your initial purchase. We’ll refund membership fees paid during that period and cancel future renewals. This covers membership fees, not investment returns.
$399/year or $50/month
Founder, EverLife Capital
Why I built EverLife
For 25 years, I built a services company in the U.S. Then, three to four years ago, I discovered longevity biotech. Helping people live longer, healthier lives felt like the most meaningful contribution I could make.
I began investing, then sold most of my company to focus on this field.
But caring about the mission didn’t mean I knew how to evaluate the companies. I lost $10,000 in each of my first two longevity biotech investments.
In investor meetings, I often heard enthusiasm for a technology, confidence in a founder or a compelling intuition. Experienced investors may have developed judgment through years of investing. As a newcomer, I needed a process I could understand and practice.
I’m a UC San Diego computer-engineering graduate, but the biology initially felt like a foreign language. It took thousands of hours of study to start making sense of the research.
That led me to develop the 25-Gate Framework, a consistent way to examine the science and business behind a longevity biotech company.
My goal is to shorten that learning curve for you. To help you understand the treatments, assess the evidence and develop your own judgment about companies, without making research a full-time job.
You’re here to build the ability to evaluate an opportunity yourself, beyond the excitement of someone else’s next stock tip.
See the dated company research history →
Review the original assessments, then follow progress and setbacks.
A few questions, answered
Do I need a biotech background?
No. Mechanisms are explained in plain English, and each exercise focuses on one skill at a time. Source links let you go deeper.
What stays free?
The weekly mechanism lesson and company overview. Paid membership unlocks the complete evaluation, focused practice and worked assessment, plus archive access while subscribed.
Will I practice all 25 criteria?
The 52-week teaching plan revisits all 25 criteria across different cases, with two additional review lessons. You can join the ongoing weekly series and use the archive while subscribed.
How do billing, cancellation and refunds work?
The annual plan charges $399 today and renews at $399/year. The monthly plan charges $50 today and renews at $50/month. Both renew automatically until canceled. Manage your subscription through your subscriber account.
For the 90-day satisfaction guarantee, email [email protected] within 90 days of your initial purchase. We will refund membership fees paid during that period and cancel future renewals. The guarantee covers membership fees, not investment losses.
Is this a stock recommendation service?
No. EverLife provides general educational research and evaluation practice. It does not provide personalized investment advice or promise financial results.
EverLife Capital is published by Consult Us, LLC. Educational content, not investment or medical advice. No investment outcome is guaranteed.
Terms · Privacy · Disclosure